文/Amber Tong 诺和诺德将支付高达26亿美元，从中国江苏恒瑞医药股份有限公司许可引进一种实验性肥胖症药丸，将这一早期药物纳入其管线，以寻求重建投资者对其在奥西金（Ozempic）和维高薇（Wegovy）等大单品之外的未来前景的信心。
By Amber Tong Novo Nordisk A/S will pay as much as $2.6 billion to license an experimental obesity pill from China’s Jiangsu Hengrui Pharmaceuticals Co., adding an early-stage drug to its pipeline as it seeks to rebuild investor confidence in its future beyond blockbusters Ozempic and Wegovy.
诺和诺德将预先支付3亿美元，获得在全球范围内（中国大陆、香港、澳门和台湾除外）开发、生产和商业化恒瑞该药物的权利。恒瑞将有资格获得基于销售额的特许权使用费。
Novo will pay $300 million upfront for rights to develop, manufacture and commercialize Hengrui’s drug globally outside mainland China, Hong Kong, Macau and Taiwan. Hengrui will be eligible for sales-based royalties.
该疗法名为HRS-1596，靶向GLP-1和GIP受体，设计为每周服用一次。
Known as HRS-1596, the treatment targets GLP-1 and GIP receptors and is designed to be taken once a week.
据这家丹麦制药公司称，它已在中国获批针对体重管理和糖尿病开展1期临床试验。
It has been cleared for Phase 1 clinical trials in China for weight management and diabetes, according to the Danish pharmaceutical company.
目前市场上的减重药丸，包括诺和诺德自己的产品，均为每日服用一次。
Weight-loss pills currently on the market, including Novo’s own, are taken once a day.
诺和诺德研发执行副总裁兼首席科学官Martin Holst Lange在声明中表示，该药物有潜力"提高该领域便利性的标准"。
The drug has potential to “raise the bar for convenience in the field,” Martin Holst Lange, Novo’s executive vice president for research & development and chief scientific officer, said in a statement.
尽管高管们承诺到2030年推出五款以上新大单品，并在2035年前新增超过230亿美元销售额，但上周他们仍让投资者感到失望，分析师指出缺乏细节披露。这些目标也被普遍认为已符合投资者预期。
Executives underwhelmed investors last week despite promising to launch more than five new blockbusters by 2030 and adding more than $23 billion in new sales by 2035, as analysts pointed to a lack of detail provided. The targets were also widely seen as already in line with investor expectations.
尽管诺和诺德和礼来公司仍主导全球减重药市场，但中国公司的竞争管线近年来激增。据一项估计，中国有超过250个候选药物在研。
Although Novo and Eli Lilly & Co. still dominate the weight-loss drug market globally, rival programs from Chinese companies have proliferated in recent years. By one estimate, China has more than 250 candidates in development.
许多已被大型药企收购：诺和诺德去年从联邦制药许可引进了一款三重受体激动剂，而阿斯利康、默克、辉瑞和再生元制药各自也宣布了针对中国开发的肥胖症药物的交易。诺和诺德表示，该恒瑞交易预计将于2026年第四季度完成。
Many of them have been picked up by large pharmaceutical companies: Novo licensed a triple receptor agonist from United Laboratories last year, while AstraZeneca Plc, Merck & Co., Pfizer Inc. and Regeneron Pharmaceuticals Inc. have each announced deals for obesity drugs developed in China. The Hengrui deal is expected to close in the fourth quarter of 2026, Novo said.